Genome Editing Market Outlook:
Genome Editing Market size was USD 8.7 billion in 2024 and is predicted to reach USD 34.5 billion by the end of 2034, increasing at a CAGR of 17.8% during the forecast period, i.e., 2025-2034. In 2025, the industry size of genome editing is assessed at USD 9.8 billion.
The worldwide and suitable patient pool in the market is increasing, highly attributed to a surge in genetic disease occurrence, including cystic fibrosis, accounting for almost 70,500 cases in the world, and sickle cell disease, accounting for approximately 100,150 patients in America. Besides, government-backed genomic strategies, including the All of Us Program by the NIH, have aimed to sequence at least 1.5 million genomes, which has escalated the need for precision therapies. Meanwhile, the supply chain dynamics for the market include APIs, such as Cas9 enzymes and guide RNAs, medical devices such as electroporation devices, and viral vectors, including Lentiviruses and AAVs, thus suitable for uplifting the overall market growth.
Moreover, investments in research, development, and deployment (RDD) have increased to USD 5.2 billion as of 2023, of which 70% has been allocated to therapeutics. According to the ITA government report, the U.S. has exported a total of USD 2.2 billion, which is readily dominated by synthetic DNA, along with viral vectors. In addition, automation in assembly lines for CAR-T cell manufacturing and CRISPR kits has effectively diminished production expenses by 20% since 2021. Besides, trade tariffs on China-based bioreactors, catering to an estimated 27%, as well as German-based electroporation systems, catering to almost 7.8%, have positively impacted procurement, thereby increasing the market exposure.
